These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 11157895)

  • 21. Clinical aspects on antibiotic resistance: upper respiratory tract infections.
    Prellner K
    Microb Drug Resist; 1995; 1(2):143-7. PubMed ID: 9158748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparative study on bacterial eradication rate and clinical efficacy of CDTR, CFPN, and FRPM for treatment of children with otitis media and lower respiratory tract infection due to Streptococcus pneumoniae and Haemophilus influenzae].
    Sakata H
    Jpn J Antibiot; 2001 May; 54 Suppl B():96. PubMed ID: 12638154
    [No Abstract]   [Full Text] [Related]  

  • 23. Antimicrobial resistance in respiratory tract pathogens.
    Stratton CW
    Expert Rev Anti Infect Ther; 2004 Aug; 2(4):641-7. PubMed ID: 15482226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Antibiotic resistance: infections of the upper respiratory tract and bronchi. When are antibiotics necessary?].
    Zellweger C; Täuber MG
    Ther Umsch; 2002 Jan; 59(1):21-9. PubMed ID: 11851042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Antibiotic therapy for patients with respiratory tract infection].
    Kasahara K; Mikasa K
    Nihon Naika Gakkai Zasshi; 2006 Nov; 95(11):2220-4. PubMed ID: 17168396
    [No Abstract]   [Full Text] [Related]  

  • 26. The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults.
    File TM
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S131-4. PubMed ID: 18029151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy.
    Thomas JK; Forrest A; Bhavnani SM; Hyatt JM; Cheng A; Ballow CH; Schentag JJ
    Antimicrob Agents Chemother; 1998 Mar; 42(3):521-7. PubMed ID: 9517926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antibiotic treatment of cystic fibrosis].
    de Montalembert M; Berche P; Lenoir G
    Ann Pediatr (Paris); 1991 Oct; 38(8):523-8. PubMed ID: 1746849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimizing the management of community-acquired respiratory tract infections in the age of antimicrobial resistance.
    Doern GV
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):821-35. PubMed ID: 17140358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infections of the upper respiratory tract, head, and neck. The role of anaerobic bacteria.
    Brook I
    Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):37-48. PubMed ID: 19667548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical implications of antimicrobial resistance for therapy.
    Macgowan AP;
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 2():ii105-14. PubMed ID: 18819975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [On the resistance of bacterial agents of respiratory tract infections].
    Roester U
    Med Welt; 1966 Sep; 39():2080-3. PubMed ID: 5920478
    [No Abstract]   [Full Text] [Related]  

  • 33. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.
    Ciofu O; Tolker-Nielsen T; Jensen PØ; Wang H; Høiby N
    Adv Drug Deliv Rev; 2015 May; 85():7-23. PubMed ID: 25477303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibiotic-nanomedicines: facing the challenge of effective treatment of antibiotic-resistant respiratory tract infections.
    Ritsema JA; der Weide HV; Te Welscher YM; Goessens WH; van Nostrum CF; Storm G; Bakker-Woudenberg IA; Hays JP
    Future Microbiol; 2018 Nov; 13():1683-1692. PubMed ID: 30499686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antibiotic resistance in respiratory tract infections: what can we do?].
    Flückiger U
    Praxis (Bern 1994); 2001 May; 90(21):931-4. PubMed ID: 11441707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Thoughts on the problem of testing germ resistance preceding antibiotic therapy of bacterial-inflammatory disorders of the respiratory tract].
    Gregori P
    Dtsch Gesundheitsw; 1966 Aug; 21(32):1517-20. PubMed ID: 5923478
    [No Abstract]   [Full Text] [Related]  

  • 37. New therapeutic options for respiratory tract infections.
    Bassetti M; Righi E; Carnelutti A
    Curr Opin Infect Dis; 2016 Apr; 29(2):178-86. PubMed ID: 26871402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections.
    Joseph J; Rodvold KA
    Expert Opin Pharmacother; 2008 Mar; 9(4):561-75. PubMed ID: 18312158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence-based guidelines for treatment of bacterial respiratory tract infections in the era of antibiotic resistance.
    Jacobs MR; Weinberg W
    Manag Care Interface; 2001 Apr; 14(4):68-80. PubMed ID: 11339025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Variations of microbial sensitivity in lower respiratory tract infections].
    Aguerre MM; Costa de Mello B
    Hoja Tisiol; 1971; 28(1-2):41-76. PubMed ID: 5173683
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.